Mergers & Acquisitions in Pharma Industry

Only available on StudyMode
  • Download(s): 99
  • Published: April 14, 2012
Open Document
Text Preview
PROJECT REPORT
ON
A Successful International Merger in India:
GlaxoSmithKline pharmaceutical industry

Table of Contents:

Declaration
Abstract
Part I –Introduction
Research Objective and justifications
Report Outline
Part-II Industry Description
GSK-The Big Picture
Factors for success in India
References
Part-III Literature review
Chapter One –Merger: An Introduction
1.1 Introduction
1.2 The Main Idea
1.3 Types of Merger
1.4 Reasons for International M&A
Chapter Summary
References
Chapter Two-Nature of Indian pharmaceutical
Industry 2.1 Introduction
2.2 Nature of Indian Pharmaceutical Industry
2.2.1 Industry Scenario
2.2.2 Market Scenario ((Projected Pharmaceutical Market, 2004-2009))
2.2.3 New Product Launches underlie market growth
2.2.5 Key Opportunities
2.2.6 FDI in Indian pharma
2.2.7 Strategy and Trends
2.2.8 Research and Development
2.2.9 SWOT Analysis
2.2.10 Mergers and Acquisitions in Pharma
2.2.11 Good Opportunities for ‘big pharma’
References
Chapter Three-Merger between Glaxo Wellcome
Smithkline Beecham
3.1 Introduction
3.2 Merger rationale
3.2.1 Rapid advances in Science and Technology
3.2.2 The growing importance of marketing power
3.2.3 The emergence of patients as consumers
3.3 Merger Benefits
3.3.1 Short term growth
3.3.2 Medium term growth
3.3.3 Long term growth
3.4 Business performance of GSK
Chapter summary
References
Chapter Four-Research Methodology
4.1 Introduction
4.2 Primary Research
4.3 Secondary Research
4.4 Sources of Information
4.5 Research design
4.6 Qualitative research
4.7 Exploratory research
4.8 Data Collection Technique
4.8.1 Primary Data
4.8.2 Exploratory Research Design Secondary Data
4.8.3 Computerized Database
4.8.4 The Interview
4.9 Limitations of study
References
Chapter Five –Factors that support the research
Objectives
5.1 Introduction
5.2 Foreign Direct Investment
5.2.1 Forms of FDI
Chapter Summary

Chapter Six-Research Findings
6.1 Introduction
6.2 About R&D of GlaxoSmithKline
6.2.1 Research Design
6.2.2 Discovering new medicines
6.2.3 Genetic Research
6.2.4 Discovery Research
6.2.5 Drug Discovery
6.2.6 Pre-Clinical Development
6.2.7 Global Commercial Strategy
6.2.8 Clinical Trails
6.2.9 Collaboration and Partnership
6.2.10 Big Pharma to launch patent protected products in India
6.2.11 Technology, Absorption, Adaptions and Innovation
6.2.12 R&D centers in India
6.2.13 Expenditure on R&D
6.3 Product making- By GSK
6.3.1 Collaboration with Galapagos
6.3.2 Collaboration with Path
6.3.3 Collaboration with IAVI
6.3.4 H5NI avian flu Strain
6.3.5 For HIV/AIDS
6.3.6 Vaccine launchers
6.3.7 Pharmaceutical Products (Progress in 2009)
6.3.8 Available products in India
6.4 Marketing strategy of GlaxoSmithKline
Chapter Summary
References

Chapter Seven – Discussion & Analysis
7.1 Introduction
7.2 Merger-Boom or Bane
7.3 Analysis//Summary
7.3.1 Rationale
7.3.2 Schemes of arrangement
7.3.3 Results of the implementation of Merger
7.3.4 Foreign exchange earnings and outgo of GlaxoSmithKline
Conclusion
Bibliography
Appendices
Annexure A-Questionnaire...
tracking img